DiaSorin shares, DIA share prices on the Stock Exchange

Everything you need to know to stay updated on the financial market. Information, trend and graph in real time on the stock exchange quotations of the major stocks on world stock exchanges.

ISIN code: IT0003492391
Sector: Healthcare technology
Industry: Specific medical equipment

DiaSorin's shares are listed on the Italian market on the Milan Stock Exchange under the ticker DIA.

Look at the history of the quotation of the share on the Milan Stock Exchange

Company Description

DiaSorin SpA is an Italian company that deals with health technology. It operates in the sectors ofimmunodiagnostics and molecular diagnostics. The company develops, manufactures and markets tests for diagnosis which are used by the medical world to investigate patient values, understand their state of health or monitor the progression of pathologies.

DiaSorin heads a group made up of 26 companies and 4 foreign branches. It produces its own tests in sites between Europe and the United States.

The company, founded in 1968, is listed on the Italian Stock Exchange since July 2007 where it is listed on the FTSE MIB index.

Immunodiagnostic technologies and molecular diagnostics work on automated platforms that are developed directly by the company together with other partner companies. Diasorin develops its research on the creation of kits for laboratories in the field of molecular diagnostics, with a particular focus on infectious diseases detectable from blood, cerebrospinal fluid, skin swabs and skin mucus.

DiaSorin tests are able to detect the presence of a specific element in the sample taken from the patient, such as viruses, hormones, etc., even in minimal quantities.

The technologies developed are open to interconnection with platforms of other diagnostic operators.

In 2020 the turnover was 881,3 million euros with a net profit of 248,3 million euros.

It has around 2.000 employees. The president is Gustavo Denegri and the CEO is Charles Rose.

Its catchphrase is «Diagnostics is for Life».

Economic and financial analysis of the company

DiaSorin born in the 1968, when the “Sorin Biomedical” by the "Nuclear Plant Research Company - Sorin". The initiative had been promoted by Fiat and Montecatini. The intent was that, through the Italian technicians trained in the United States, to specialize in the development of biomedical equipment for in vitro diagnostics.

Change name to Sorin Diagnostics and in 1997, it acquired in the United States the Incstar Inc.specialized company in the sector. Subsequently it spins off the activities concerning diagnostics in the company DiaSorin Srl which shortly after was sold to American Standard International.

DiaSorin was officially born in 2000, through an operation of buyout management led by Carlo Rosa and supported by Gustavo Denegri. 
The company name derives from the acronym of Sorin “Nuclear plant research company” and Dia which stands for Diagnostics.

In 2001 it acquired the BYC Sangtec and with it the rights to the platform "Liaison"based on chemiluminescence technology (CLIA). This platform allows you to analyze specialty diagnostic tests with high automation, both in modality stand alone and using Laboratory Automation Systems produced by other companies. In 2008 he acquired Biotrin, world leader for Parvovirus testing, and by Eiken Chemical the license and use of the technology “LAMP”, thus officially entering the business molecular.

It begins to open branches in China, Mexico, Israel and India.

Detect in 2010 Murex and the products of Abbott Laboratories. In 2011 he acquired NorDiag, specialized in the extrusion of nucleic acids. In 2015 he signed a commercial distribution agreement with Beckman Coulter for registration in the US market of automated tests for the analysis of hepatitis and retroviruses. In 2016 he took over 300 million from the company Quest Diagnostics the immunodiagnostics and molecular diagnostics arm of Focus Diagnostics with a research center and facility in Cypress, California. In September 2017 the company took over from Siemens Healthcare €47,5 million for the Elisa test portfolio for infectious diseases.

He entered into a partnership with in 2017 qiagen to offer an automated solution for the diagnosis of latent tuberculosis. In 2018 he signed a partnership with meridian for the distribution of the Helicobacter pylori test in the USA and Great Britain and the development of new gastrointestinal panel tests.

In 2020 DiaSorin signed an exclusive licensing agreement with ttp for the automation of diagnostic tests. In September 2020 DiaSorin e MeMed enter into a strategic partnership for the development and commercialization of a diagnostic solution based on the patient's immune response.

In February 2021 Diasorin received approval for the marketing of the Liaison Lyme IgM and Liaison Lyme IgG tests by the US FDA.

One of the latest transactions was the purchase of the American company for a value of 1,2 billion euros luminex which took place in April 2021.

Currently the production plants are located in Saluggia and Gerenzano in Italy, Dietzenbach in Germany, Stillwater and Cypress in the USA, Dartford in the United Kingdom.

The research team consists of approximately 200 people who are dedicated to the development of solutions for specialty tests to support doctors and laboratory managers in order to elaborate the diagnoses of even very particular diseases. The analysis kits are intended for the immunodiagnostic sectors concerning infectious diseases, gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-haematology, autoimmunity.

DiaSorin currently has approximately 120 approved tests for immunological analysis.

The sale of products in the various markets where it is present is managed by satellite companies of the DiaSorin group. In countries where there is no direct sales, it uses an international network of independent distributors.

Diasorin, where it is present, also promotes activities at the level of social development especially in Piedmont.

The company has been listed on the Italian Stock Exchange since 2007 and has been present in the FTSE Italia Mid Cap index since 2018.

The shareholders is composed by:

• 57% Finde SS
• 8,5% Carlo Rosa
• 3% T. Rowe Price Associates, Inc.

The rest equal to about 31% is given by the stock market.